Printer Friendly

CELL GENESYS ADDS TWO KEY PRODUCT DEVELOPMENT DIRECTORS

 FOSTER CITY, Calif., Aug. 26 /PRNewswire/ -- Cell Genesys Inc. (NASDAQ: CEGE) today announced the addition of two senior staff in newly- created positions in product development. Joining the company are Catherine Lucas, Ph.D., 39, as director of assay development and quality control and Brian W. McGuire, Ph.D., 39, as director of clinical research. Previously, Lucas was with Genentech Inc. and McGuire was at Amgen Inc.
 "We are pleased to have Catherine Lucas and Brian McGuire bring their extensive experience in biotechnology product development to Cell Genesys," said Stephen A. Sherwin, M.D., president and chief executive officer. "We believe that we have now assembled the team needed to advance our product development programs toward human clinical trials."
 For the past eight years, Lucas was with Genentech, most recently as a senior scientist specializing in immunoassays for product development. Lucas is an author on more than 25 scientific publications and previously served as National Institutes of Health postdoctoral fellow at Stanford University School of Medicine. She received a doctorate in neurochemistry from the University of Sciences in Paris, where she also earned a master's in biochemistry and a bachelor's in chemistry and biology.
 McGuire was with Amgen for four years, where he was most recently associate director of clinical affairs and product development team leader for Amgen's bone marrow stem cell factor project. For the previous nine years, he held clinical research positions at other pharmaceutical companies, including Lederle Laboratories and American McGaw. McGuire is an author on 25 scientific publications. He received a doctorate in biochemistry from Vanderbilt University, where he also earned a bachelor's in molecular biology.
 Since the beginning of the year, Cell Genesys also has announced the addition of directors in three other newly-created product development positions. Bridget Binko joined the company as director of regulatory affairs from IDEC Pharmaceuticals Corp.; David F. Broad, Ph.D., came to the company from Celltech Ltd. as director of cell culture development; and William Mueller, previously from Amgen, joined the company as director of process recovery. Krisztina M. Zsebo, Ph.D., who joined Cell Genesys a year ago from Amgen, last month was promoted to vice president of product development and Daniel F. Hoth, M.D., joined the company in June as senior vice president and chief medical officer after a 13-year career at the National Institutes of Health, most recently as director of the AIDS Division of the National Institute of Allergy and Infectious Disease.
 Cell Genesys is a leader in the application of gene targeting technology to the development of human therapeutic products. Gene targeting is a cellular genetic engineering technology which enables precise and permanent activation, inactivation and replacement of specific genes in living cells. The company is applying gene targeting and related technologies to develop products in three areas: universal cell transplant products, therapeutic protein products and human monoclonal antibody products.
 -0- 8/26/93
 /CONTACT: Stephen A. Sherwin, president and chief executive officer of Cell Genesys, 415-358-9600, ext. 212/
 (CEGE)


CO: Cell Genesys Inc. ST: California IN: MTC SU: PER

SG-JB -- SF006 -- 6170 08/26/93 13:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 26, 1993
Words:516
Previous Article:EDDIE BAUER INC. TRIES ON MEN'S FRAGRANCE
Next Article:JMC GROUP INITIATES CASH DIVIDEND AND AUTHORIZES STOCK REPURCHASE PROGRAM
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters